---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-238850"
form_type: "8-K/A"
ticker: "DNTH"
cik: "0001690585"
company_name: "Dianthus Therapeutics, Inc. /DE/"
filed_at: "2023-09-21T23:59:59+00:00"
generated_at: "2026-06-10T10:48:43.603378+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Dianthus files OpCo historical financials; pro forma cash runway into Q2 2026

## Summary
- OpCo net losses: $18.2M (H1 2023), $28.5M (FY2022), $13.1M (FY2021).
- Pro forma combined cash sufficient to fund operations into Q2 2026 per risk factors.
- Board classified: Class I (2025 AGM), Class II (2026 AGM), Class III (2024 AGM).
- Shares outstanding as of 9/21/2023: 14,813,295.
- Material weakness identified in internal control over financial reporting.

## SEC filing metadata
- accession: 0001193125-23-238850
- form_type: 8-K/A
- ticker: DNTH
- cik: 0001690585
- company_name: Dianthus Therapeutics, Inc. /DE/
- filed_at: 2023-09-21T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690585/000119312523238850/0001193125-23-238850-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690585/000119312523238850/d520077d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-238850
- JSON: https://secwatch.observer/filing/0001193125-23-238850.json
- Plain text: https://secwatch.observer/filing/0001193125-23-238850.txt

## Key facts
- Executive change
  Tomas Kiselak was appointed as Class II Director at Dianthus Therapeutics, Inc. /DE/.
  - Action: appointed
  - Role: Class II Director
  source text: As previously disclosed, on September 11, 2023, Marino Garcia and Paula Soteropoulos were appointed as Class I directors of the Board, Tomas Kiselak and Jonathan Violin, Ph.D., were appointed as Class II directors of the Board and Leon O. Moulder, Jr. and Lei Meng were appointed as Class III directors of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1690585/000119312523238850/0001193125-23-238850-index.htm
- Executive change
  Paula Soteropoulos was appointed as Class I Director at Dianthus Therapeutics, Inc. /DE/.
  - Action: appointed
  - Role: Class I Director
  source text: As previously disclosed, on September 11, 2023, Marino Garcia and Paula Soteropoulos were appointed as Class I directors of the Board, Tomas Kiselak and Jonathan Violin, Ph.D., were appointed as Class II directors of the Board and Leon O. Moulder, Jr. and Lei Meng were appointed as Class III directors of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1690585/000119312523238850/0001193125-23-238850-index.htm
- Executive change
  Jonathan Violin, Ph.D. was appointed as Class II Director at Dianthus Therapeutics, Inc. /DE/.
  - Action: appointed
  - Role: Class II Director
  source text: As previously disclosed, on September 11, 2023, Marino Garcia and Paula Soteropoulos were appointed as Class I directors of the Board, Tomas Kiselak and Jonathan Violin, Ph.D., were appointed as Class II directors of the Board and Leon O. Moulder, Jr. and Lei Meng were appointed as Class III directors of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1690585/000119312523238850/0001193125-23-238850-index.htm
- Executive change
  Lei Meng was appointed as Class III Director at Dianthus Therapeutics, Inc. /DE/.
  - Action: appointed
  - Role: Class III Director
  source text: As previously disclosed, on September 11, 2023, Marino Garcia and Paula Soteropoulos were appointed as Class I directors of the Board, Tomas Kiselak and Jonathan Violin, Ph.D., were appointed as Class II directors of the Board and Leon O. Moulder, Jr. and Lei Meng were appointed as Class III directors of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1690585/000119312523238850/0001193125-23-238850-index.htm
- Executive change
  Marino Garcia was appointed as Class I Director at Dianthus Therapeutics, Inc. /DE/.
  - Action: appointed
  - Role: Class I Director
  source text: As previously disclosed, on September 11, 2023, Marino Garcia and Paula Soteropoulos were appointed as Class I directors of the Board, Tomas Kiselak and Jonathan Violin, Ph.D., were appointed as Class II directors of the Board and Leon O. Moulder, Jr. and Lei Meng were appointed as Class III directors of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1690585/000119312523238850/0001193125-23-238850-index.htm
- Executive change
  Leon O. Moulder, Jr. was appointed as Class III Director at Dianthus Therapeutics, Inc. /DE/.
  - Action: appointed
  - Role: Class III Director
  source text: As previously disclosed, on September 11, 2023, Marino Garcia and Paula Soteropoulos were appointed as Class I directors of the Board, Tomas Kiselak and Jonathan Violin, Ph.D., were appointed as Class II directors of the Board and Leon O. Moulder, Jr. and Lei Meng were appointed as Class III directors of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1690585/000119312523238850/0001193125-23-238850-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.